December 4, 2006 -- Pfizer fell 10% after abandoning its most promising drug, the cholesterol treatment torcetrapid; companies with potential rivals to the Pfizer drug moved higher; these included Abbott, Isis and Oscient; Onyx dropped 30% lower after announcing that Nexavar failed a Phase III trial for skin cancer; Micromet soared after receiving a $10 million milestone; Sangamo bought the angiogenesis program from Edwards Lifesciences; AstraZeneca paid $10.25 million to in-license the Chinese rights to Cubicin from Cubist Pharma; and CV Therapeutics said regadenoson met its endpoints in the second of two Phase III trials. The Centient Biotech 200™ rose 35 points to 3982, an increase of .89%. More details...
